Treatment of pervasive developmental disorders with redox-active therapeutics
AssigneePTC Therapeutics, Inc.
InventorsGuy M. Miller, Viktoria Kheifets
Life of this patent
Estimating the term…
Abstract
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Claims20
A method of reducing one or more symptoms associated with, or of treating or suppressing a pervasive developmental disorder (PDD) or attention deficit/hyperactivity disorder (ADHD), in a patient in need thereof comprising administering a therapeutically effective amount or physiologically effective amount of one or more compounds selected from the group consisting of Formula I, Formula II, and mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen, and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate, or a hydrate thereof.
A method of reducing one or more symptoms associated with, or of treating or suppressing Rett's disorder or Rett syndrome, in a patient in need thereof comprising administering a therapeutically effective amount or physiologically effective amount of one or more compounds selected from the group consisting of Formula I, Formula II, and mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen, and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate, or a hydrate thereof.
A method of reducing one or more symptoms associated with, or of treating or suppressing autistic spectrum disorder, in a patient in need thereof comprising administering a therapeutically effective amount or physiologically effective amount of one or more compounds selected from the group consisting of Formula I, Formula II, and mixtures thereof,
- wherein,
- the bonds indicated with a dashed line are all single bonds or are all double bonds;
- R1, R2, and R3 are independently selected from the group consisting of H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, halogen, and CN;
- or a stereoisomer, a mixture of stereoisomers, a solvate, or a hydrate thereof.
Dependencies are inferred from the claim text.